Drug Profile
SM 07883
Alternative Names: SM-07883Latest Information Update: 31 Aug 2023
Price :
$50
*
At a glance
- Originator Samumed
- Developer Biosplice Therapeutics
- Class Antidementias; Small molecules
- Mechanism of Action DYRK kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
- Research Tauopathies; Traumatic brain injuries
Most Recent Events
- 31 Aug 2023 Early research in Tauopathies in USA (PO), prior to August 2023 (Biosplice Therapeutics pipeline, August 2023)
- 31 Aug 2023 Early research in Traumatic brain injuries in USA (PO), prior to August 2023 (Biosplice Therapeutics pipeline, August 2023)
- 31 Aug 2023 Preclinical trials in Alzheimer's disease in USA (PO), prior to August 2023 (Biosplice Therapeutics pipeline, August 2023)